A study showing that randomized controlled trials don’t cite much of the preceding literature suggests there’s a problem, but it’s unclear exactly what the problem is.
An interesting and entertaining debunking of some obvious fluffs in medical science, with a chilling reminder of how libel laws in some countries can kill scientific discourse.
With the economic benefits of open access open to reinterpretation, will the moral benefits prove sufficient to withstand the coming scrutiny? And will it all begin a race to the bottom?
After wondering at the supposed burden of peer-review, more evidence emerged that it still works well, and is probably less taxing than other alternatives.
The movement to publish more and more demands that we find ways to preserve the trust we’ve built while taking advantage of the sunlight public availability can provide.